INT173975

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2003
Last Reported 2008
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 7
Disease Relevance 5.63
Pain Relevance 0.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Cd52)
Anatomy Link Frequency
B lymphocytes 3
T lymphocytes 2
hematopoietic stem cells 1
lymphocytes 1
Cd52 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammatory mediators 4 54.76 Quite High
Etanercept 16 50.56 Quite High
Infliximab 32 49.36 Quite Low
cytokine 20 40.24 Quite Low
methotrexate 124 5.00 Very Low Very Low Very Low
cva 16 5.00 Very Low Very Low Very Low
Inflammation 12 5.00 Very Low Very Low Very Low
Paracetamol 12 5.00 Very Low Very Low Very Low
withdrawal 11 5.00 Very Low Very Low Very Low
Antihistamine 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Chronic Lymphoid Leukemia 192 99.84 Very High Very High Very High
Malignant Neoplastic Disease 26 99.84 Very High Very High Very High
Lymphatic System Cancer 3 95.24 Very High Very High Very High
Disease 230 95.08 Very High Very High Very High
Apoptosis 13 93.76 High High
Cytomegalovirus Infection 151 89.68 High High
Death 13 87.88 High High
Sepsis 19 87.68 High High
Nocardia Infection 3 86.36 High High
Mycobacterial Infection 3 85.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The difference in clinical results between rituximab, a chimeric human-mouse anti-CD20, and alemtuzumab may be related to the relative expression of CD20 and CD52 on malignant lymphocytes; the level of CD20 expression in patients with B-CLL is low, in comparison with other B-cell lymphomas and normal B-cells (Rossmann et al 2001).
Gene_expression (expression) of CD52 in B-cell associated with chronic lymphoid leukemia, malignant neoplastic disease and lymphatic system cancer
1) Confidence 0.28 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727786 Disease Relevance 0.91 Pain Relevance 0
These include: a) variable expression of CD20 and CD52 on CLL cells of individual patients; b) synergistic activity in anatomic compartments such as lymphnode sites (where rituximab is expected to be more effective), versus marrow, (better clearance of malignant lymphocytes with alemtuzumab); c) engagement of distinct intracellular signaling pathways resulting in apoptotic cell death.
Gene_expression (expression) of CD52 in lymphocytes associated with chronic lymphoid leukemia, malignant neoplastic disease, apoptosis and death
2) Confidence 0.28 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727786 Disease Relevance 1.46 Pain Relevance 0
Alemtuzumab (CAMPATH-1H) is a humanized monoclonal antibody directed against cell surface CD52 expressed on normal and malignant B lymphocytes and T lymphocytes, on natural killer cells, and on macrophages.
Gene_expression (expressed) of CD52 in T lymphocytes associated with malignant neoplastic disease
3) Confidence 0.26 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC165064 Disease Relevance 0.65 Pain Relevance 0.05
Alemtuzumab (CAMPATH-1H) is a humanized monoclonal antibody directed against cell surface CD52 expressed on normal and malignant B lymphocytes and T lymphocytes, on natural killer cells, and on macrophages.
Gene_expression (expressed) of CAMPATH-1H in T lymphocytes associated with malignant neoplastic disease
4) Confidence 0.26 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC165064 Disease Relevance 0.71 Pain Relevance 0.05
Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen expressed at high density on most normal and malignant B and T lymphocytes, but not on hematopoietic stem cells (Gilleece et al 1993).
Neg (not) Gene_expression (expressed) of CD52 in hematopoietic stem cells associated with malignant neoplastic disease
5) Confidence 0.24 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727786 Disease Relevance 0.53 Pain Relevance 0
Alemtuzumab (CAMPATH-1H) is a humanized monoclonal antibody directed against cell surface CD52 expressed on normal and malignant B lymphocytes and T lymphocytes, on natural killer cells, and on macrophages.
Gene_expression (expressed) of CD52 in B lymphocytes associated with malignant neoplastic disease
6) Confidence 0.09 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC165064 Disease Relevance 0.65 Pain Relevance 0.05
Alemtuzumab (CAMPATH-1H) is a humanized monoclonal antibody directed against cell surface CD52 expressed on normal and malignant B lymphocytes and T lymphocytes, on natural killer cells, and on macrophages.
Gene_expression (expressed) of CAMPATH-1H in B lymphocytes associated with malignant neoplastic disease
7) Confidence 0.09 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC165064 Disease Relevance 0.71 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox